Related references
Note: Only part of the references are listed.Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)
M. Arpinati et al.
BONE MARROW TRANSPLANTATION (2009)
Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy
Denis M. Schewe et al.
CANCER RESEARCH (2009)
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Han-Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Immunological methods to quantify and characterize proteasome complexes: Development and application
Matthias Majetschak et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Intermediate-type 20 S proteasomes in HeLa cells: Asymmetric subunit composition, diversity and adaptation
Nicola Klare et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Effects of aneuploidy on cellular physiology and cell division in haploid yeast
Eduardo M. Torres et al.
SCIENCE (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M. Kraus et al.
LEUKEMIA (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition:: Therapeutic implications
Y Fernández et al.
CANCER RESEARCH (2005)
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue
L Chen et al.
CANCER RESEARCH (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
CR Berkers et al.
NATURE METHODS (2005)
Phosphorylation of the α-subunit of the eukaryotic initiation factor-2 (eIF2α) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition
HY Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
β2 subunit propeptides influence cooperative proteasome assembly
M De et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Transcriptome analysis of human autosomal trisomy
DR FitzPatrick et al.
HUMAN MOLECULAR GENETICS (2002)
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
JR Pollack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective
JWA Findlay et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2000)
Share Paper
